Requirement of aggregation propensity of Alzheimer amyloid peptides for neuronal cell surface binding
<p>Abstract</p> <p>Background</p> <p>Aggregation of the amyloid peptides, Aβ40 and Aβ42, is known to be involved in the pathology of Alzheimer's disease (AD). Here we investigate the relationship between peptide aggregation and cell surface binding of three forms o...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2007-05-01
|
| Series: | BMC Neuroscience |
| Online Access: | http://www.biomedcentral.com/1471-2202/8/29 |
| _version_ | 1811266771992182784 |
|---|---|
| author | McLaurin JoAnne Bateman David A Chakrabartty Avijit |
| author_facet | McLaurin JoAnne Bateman David A Chakrabartty Avijit |
| author_sort | McLaurin JoAnne |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Aggregation of the amyloid peptides, Aβ40 and Aβ42, is known to be involved in the pathology of Alzheimer's disease (AD). Here we investigate the relationship between peptide aggregation and cell surface binding of three forms of Aβ (Aβ40, Aβ42, and an Aβ mutant).</p> <p>Results</p> <p>Using confocal microscopy and flow cytometry with fluorescently labelled Aβ, we demonstrate a correlation between the aggregation propensity of the Alzheimer amyloid peptides and their neuronal cell surface association. We find that the highly aggregation prone Aβ42 associates with the surface of neuronal cells within one hour, while the less aggregation prone Aβ40 associates over 24 hours. We show that a double mutation in Aβ42 that reduces its aggregation propensity also reduces its association with the cell surface. Furthermore, we find that a cell line that is resistant to Aβ cytotoxicity, the non-neuronal human lymphoma cell line U937, does not bind either Aβ40 or Aβ42.</p> <p>Conclusion</p> <p>Taken together, our findings reveal that amyloid peptide aggregation propensity is an essential determinant of neuronal cell surface association. We anticipate that our approach, involving Aβ imaging in live cells, will be highly useful for evaluating the efficacy of therapeutic drugs that prevent toxic Aβ association with neuronal cells.</p> |
| first_indexed | 2024-04-12T20:49:21Z |
| format | Article |
| id | doaj.art-802b9bedde1c4ab38a18ad2093993874 |
| institution | Directory Open Access Journal |
| issn | 1471-2202 |
| language | English |
| last_indexed | 2024-04-12T20:49:21Z |
| publishDate | 2007-05-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Neuroscience |
| spelling | doaj.art-802b9bedde1c4ab38a18ad20939938742022-12-22T03:17:10ZengBMCBMC Neuroscience1471-22022007-05-01812910.1186/1471-2202-8-29Requirement of aggregation propensity of Alzheimer amyloid peptides for neuronal cell surface bindingMcLaurin JoAnneBateman David AChakrabartty Avijit<p>Abstract</p> <p>Background</p> <p>Aggregation of the amyloid peptides, Aβ40 and Aβ42, is known to be involved in the pathology of Alzheimer's disease (AD). Here we investigate the relationship between peptide aggregation and cell surface binding of three forms of Aβ (Aβ40, Aβ42, and an Aβ mutant).</p> <p>Results</p> <p>Using confocal microscopy and flow cytometry with fluorescently labelled Aβ, we demonstrate a correlation between the aggregation propensity of the Alzheimer amyloid peptides and their neuronal cell surface association. We find that the highly aggregation prone Aβ42 associates with the surface of neuronal cells within one hour, while the less aggregation prone Aβ40 associates over 24 hours. We show that a double mutation in Aβ42 that reduces its aggregation propensity also reduces its association with the cell surface. Furthermore, we find that a cell line that is resistant to Aβ cytotoxicity, the non-neuronal human lymphoma cell line U937, does not bind either Aβ40 or Aβ42.</p> <p>Conclusion</p> <p>Taken together, our findings reveal that amyloid peptide aggregation propensity is an essential determinant of neuronal cell surface association. We anticipate that our approach, involving Aβ imaging in live cells, will be highly useful for evaluating the efficacy of therapeutic drugs that prevent toxic Aβ association with neuronal cells.</p>http://www.biomedcentral.com/1471-2202/8/29 |
| spellingShingle | McLaurin JoAnne Bateman David A Chakrabartty Avijit Requirement of aggregation propensity of Alzheimer amyloid peptides for neuronal cell surface binding BMC Neuroscience |
| title | Requirement of aggregation propensity of Alzheimer amyloid peptides for neuronal cell surface binding |
| title_full | Requirement of aggregation propensity of Alzheimer amyloid peptides for neuronal cell surface binding |
| title_fullStr | Requirement of aggregation propensity of Alzheimer amyloid peptides for neuronal cell surface binding |
| title_full_unstemmed | Requirement of aggregation propensity of Alzheimer amyloid peptides for neuronal cell surface binding |
| title_short | Requirement of aggregation propensity of Alzheimer amyloid peptides for neuronal cell surface binding |
| title_sort | requirement of aggregation propensity of alzheimer amyloid peptides for neuronal cell surface binding |
| url | http://www.biomedcentral.com/1471-2202/8/29 |
| work_keys_str_mv | AT mclaurinjoanne requirementofaggregationpropensityofalzheimeramyloidpeptidesforneuronalcellsurfacebinding AT batemandavida requirementofaggregationpropensityofalzheimeramyloidpeptidesforneuronalcellsurfacebinding AT chakrabarttyavijit requirementofaggregationpropensityofalzheimeramyloidpeptidesforneuronalcellsurfacebinding |